While the maintenance of a Buy rating suggests continued confidence in CARISMA Therapeutics' fundamentals, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price. However, the overall positive stance is likely to support investor sentiment.